Morganka / Shutterstock.com
In the competitive world of cancer treatment it’s becoming ever more important to stand out from the crowd. LSIPR speaks to TapImmune’s chief executive Glynn Wilson on why he thinks the company does.
In just five years Glynn Wilson, chief executive of TapImmune, estimates the Seattle-based company will be worth more than a $1 billion. It’s a big claim to make for a company that currently is not making money but Wilson sees no reason why it can’t aim for the top.
The company’s primary function is treating cancer and infectious disease through immunotherapy. Rather than using traditional chemotherapy techniques, which seek to kill cancerous cells, TapImmune’s philosophy centres on boosting the body’s immune system to fight disease.
“The real problem we are trying to solve is finding a way to stimulate the body’s cellular immune system to kill cancer cells and virally infected cells,” Wilson tells LSIPR.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
cancer treatment; patents; patent applications; TapImmune